Therefore, as PDE5 is critical for the intracellular regulation of cGMP levels, this enzyme is the target molecule for the action of PDE5 inhibitors (PDE5I), the first line pharmacological therapy currently used for the treatment of erectile dysfunction (ED) [8]. Here, PDE5A is linked to erectile dysfunction.